Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary management.

These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results. This is an ASCO Meeting ...